266 related articles for article (PubMed ID: 23209624)
1. Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.
Sarntivijai S; Xiang Z; Shedden KA; Markel H; Omenn GS; Athey BD; He Y
PLoS One; 2012; 7(11):e49941. PubMed ID: 23209624
[TBL] [Abstract][Full Text] [Related]
2. Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
Lee H; Kim HJ; Choe YJ; Shin JY
Vaccine; 2020 Jul; 38(34):5464-5473. PubMed ID: 32600907
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.
Moro P; Baumblatt J; Lewis P; Cragan J; Tepper N; Cano M
Drug Saf; 2017 Feb; 40(2):145-152. PubMed ID: 27988883
[TBL] [Abstract][Full Text] [Related]
4. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
[TBL] [Abstract][Full Text] [Related]
5. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
[TBL] [Abstract][Full Text] [Related]
6. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
[TBL] [Abstract][Full Text] [Related]
8. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.
Simpson CR; Lone NI; Kavanagh K; Englishby T; Robertson C; McMenamin J; Wissman BV; Vasileiou E; Butler CC; Ritchie LD; Gunson R; Schwarze J; Sheikh A
Health Technol Assess; 2020 Dec; 24(67):1-66. PubMed ID: 33256892
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System.
Muhammad R; Haber P; Broder K; Leroy Z; Ball R; Braun MM; Davis RL; McMahon AW
Pediatr Infect Dis J; 2011 Jan; 30(1):e1-8. PubMed ID: 21042229
[TBL] [Abstract][Full Text] [Related]
11. Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.
Haber P; Moro PL; Cano M; Vellozzi C; Lewis P; Woo EJ; Broder K
J Pediatric Infect Dis Soc; 2015 Sep; 4(3):205-13. PubMed ID: 26407428
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis.
Minozzi S; Lytras T; Gianola S; Gonzalez-Lorenzo M; Castellini G; Galli C; Cereda D; Bonovas S; Pariani E; Moja L
EClinicalMedicine; 2022 Apr; 46():101331. PubMed ID: 35360146
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
[TBL] [Abstract][Full Text] [Related]
14. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children.
Hoft DF; Babusis E; Worku S; Spencer CT; Lottenbach K; Truscott SM; Abate G; Sakala IG; Edwards KM; Creech CB; Gerber MA; Bernstein DI; Newman F; Graham I; Anderson EL; Belshe RB
J Infect Dis; 2011 Sep; 204(6):845-53. PubMed ID: 21846636
[TBL] [Abstract][Full Text] [Related]
15. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.
Bardenheier BH; Duderstadt SK; Engler RJ; McNeil MM
Vaccine; 2016 Aug; 34(37):4406-14. PubMed ID: 27449076
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
[TBL] [Abstract][Full Text] [Related]
17. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.
Carter NJ; Curran MP
Drugs; 2011 Aug; 71(12):1591-622. PubMed ID: 21861544
[TBL] [Abstract][Full Text] [Related]
18. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel.
Wang Z; Tobler S; Roayaei J; Eick A
JAMA; 2009 Mar; 301(9):945-53. PubMed ID: 19255113
[TBL] [Abstract][Full Text] [Related]
19. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
[TBL] [Abstract][Full Text] [Related]
20. Safety of influenza vaccines.
Kelso JM
Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):383-8. PubMed ID: 22766619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
